Another world's best anti-microbial

[Guest guest]

February 26, 2009 08:30 AM Eastern Time

World Renowned Microbiologist Confirms BioNeutral’s YgieneTM Formula As the Best of the Best When it Comes to Overall Antimicrobial Performance

NEWARK, N.J.--(BUSINESS WIRE)--BioNeutral Group, Inc. (OTCBB: BONU), a chemical technology-based Life Science company with novel combinational chemistry for the military, healthcare, industrial and consumer markets, announced today that Dr. Philip M. Tierno Jr., Ph.D., has tested and confirmed BioNeutral's YgieneTM MG/S efficacy and stated:

"There is nothing better. (Virtually nothing compares with it.)

There is nothing that works faster. (Kills in seconds)

There is nothing that has a more complete kill. (Kills 100% of organisms)

There is nothing wider in spectrum. (Kills any and all microbes)

And it is an environmentally GREEN product. (It eventually breaks down into innocuous substances.)"

Dr. Tierno is the Director of Clinical Microbiology and Diagnostic Immunology at New York University Langone Medical Center, and is Clinical Professor of Microbiology and Pathology at the New York University School of Medicine. He is a highly respected and world renowned microbiologist with more than 35 years of experience in the fields of Clinical and Medical Microbiology. For more than 30 years Dr. Tierno has studied the effects of germicides and disinfectants on microbes.

BioNeutral’s YgieneTM MG/S is a unique world class antimicrobial sterilant, meaning it is bactericidal, virucidal and sporicidal leaving no harmful living organisms.

As a military grade formulation it could be used by first responders in Homeland Security and military circumstances where biological weapons pose a threat – including such lethal organisms as anthrax.

At hospitals and health care facilities, YgieneTM HS (sterilant) could be used on all hard surfaces to help eliminate the nearly 1.5 million hospital acquired infections which contribute to 150,000 lost lives a year in the U.S. alone. YgieneTM could be used to quickly sterilize equipment or surgical devices. YgieneTM works at room temperature and is extremely fast acting.

Dr. Andy Kielbania, Ph.D., Chief Scientist of BioNeutral Group, Inc. stated, “Based on Dr. Tierno’s years of research and work in the field of microbiology and his recent findings regarding the performance of our Ygieneâ„¢ formulation, BioNeutral [in compliance with our objective] has set a new standard in disinfection for the health care, industrial, military and consumer markets which will save countless lives, impact tens of millions of people and be kinder on the planet and our environment.â€

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a novel combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene™ and Ogiene™, which are eco-friendly and include natural and common ingredients which are found in baby products and in every day foods. The Company has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral’s proprietary platform technology has been proven effective in surface, water and airborne applications.

More information about the Company may be found at www.bioneutralgroup.com

Forward-Looking Statements

BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name YgieneTMâ„¢ and are not yet available for sale in the United States.

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of BioNeutral Group can be found in the filings of BioNeutral Group with the U.S. Securities and Exchange Commission.

Contacts

BioNeutral Group Inc. J. Browand, President and CEOsteve@...orInvestor RelationsCorporate Evolutions, Inc.Toll Free: info@...www.corporateevolutions.com

Permalink: http://www.businesswire.com/news/google/20090226005171/en

Sharon Noonan Kramer You're invited to Hollywood's biggest party: Get s updates, red carpet pics and more at Moviefone.